Paracetamol (Acetaminophen) in stroke 2 (PAIS 2): Protocol for a randomized, placebo-controlled, double-blind clinical trial to assess the effect of high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of 36.5 degrees C or above

التفاصيل البيبلوغرافية
العنوان: Paracetamol (Acetaminophen) in stroke 2 (PAIS 2): Protocol for a randomized, placebo-controlled, double-blind clinical trial to assess the effect of high-dose paracetamol on functional outcome in patients with acute stroke and a body temperature of 36.5 degrees C or above
المؤلفون: Ritu Saxena, Ale Algra, Heleen M. den Hertog, Frank Jan de Jong, Diederik W.J. Dippel, Hester F. Lingsma, Peter J. Koudstaal, H. Maarten A. van Gemert, A. H C M L Tobien Schreuder, Inger R. de Ridder, Jordie H. van Tuijl, Annemieke Ruitenberg, L. Jaap Kappelle, E. Lisette Maasland, Peter Oomes, H. Bart van der Worp
المساهمون: Neurology, Public Health
المصدر: International Journal of Stroke, 10(3), 457-462. SAGE Publications Ltd
بيانات النشر: SAGE Publications Ltd, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Male, Antipyretics, Fever, Placebo, Body Temperature, law.invention, Clinical Protocols, Double-Blind Method, Randomized controlled trial, law, Modified Rankin Scale, medicine, Humans, Multicenter Studies as Topic, Stroke, Acetaminophen, Randomized Controlled Trials as Topic, Intracerebral hemorrhage, Dose-Response Relationship, Drug, business.industry, digestive, oral, and skin physiology, Odds ratio, medicine.disease, Clinical trial, Neurology, Anesthesia, Female, business, medicine.drug
الوصف: Rationale In the first hours after stroke onset, subfebrile temperatures and fever have been associated with poor functional outcome. In the first Paracetamol (Acetaminophen) in Stroke trial, a randomized clinical trial of 1400 patients with acute stroke, patients who were treated with high-dose paracetamol showed more improvement on the modified Rankin Scale at three-months than patients treated with placebo, but this difference was not statistically significant. In the 661 patients with a baseline body temperature of 37·0°C or above, treatment with paracetamol increased the odds of functional improvement (odds ratio 1·43; 95% confidence interval: 1·02–1·97). This relation was also found in the patients with a body temperature of 36·5°C or higher (odds ratio 1·31; 95% confidence interval 1·01–1·68). These findings need confirmation. Aim The study aims to assess the effect of high-dose paracetamol in patients with acute stroke and a body temperature of 36·5°C or above on functional outcome. Design The Paracetamol (Acetaminophen) In Stroke 2 trial is a multicenter, randomized, double-blind, placebo-controlled clinical trial. We use a power of 85% to detect a significant difference in the scores on the modified Rankin Scale of the paracetamol group compared with the placebo group at a level of significance of 0·05 and assume a treatment effect of 7%. Fifteen-hundred patients with acute ischemic stroke or intracerebral hemorrhage and a body temperature of 36·5°C or above will be included within 12 h of symptom onset. Patients will be treated with paracetamol in a daily dose of six-grams or matching placebo for three consecutive days. The Paracetamol (Acetaminophen) In Stroke 2 trial has been registered as NTR2365 in The Netherlands Trial Register. Study outcomes The primary outcome will be improvement on the modified Rankin Scale at three-months as analyzed by ordinal logistic regression. Discussion If high-dose paracetamol will be proven effective, a simple, safe, and extremely cheap therapy will be available for many patients with acute stroke worldwide.
تدمد: 1747-4949
1747-4930
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964b810f911f60ed1d75bf469b9a0a9eTest
https://doi.org/10.1111/ijs.12053Test
حقوق: CLOSED
رقم الانضمام: edsair.doi.dedup.....964b810f911f60ed1d75bf469b9a0a9e
قاعدة البيانات: OpenAIRE